Publicaciones en colaboración con investigadores/as de Hospital Universitario La Fe (14)

2024

  1. Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR–MASH score

    Liver International, Vol. 44, Núm. 1, pp. 202-213

2023

  1. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 8, pp. 594-602

  2. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 150-162

2022

  1. Automated Whole-Liver MRI Segmentation to Assess Steatosis and Iron Quantification in Chronic Liver Disease

    Radiology, Vol. 302, Núm. 2, pp. 345-354

2021

  1. Digital pathology enables automated and quantitative assessment of inflammatory activity in patients with chronic liver disease

    Biomolecules, Vol. 11, Núm. 12

2019

  1. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice-Vie-KinD study

    PLoS ONE, Vol. 14, Núm. 9

2017

  1. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

  2. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort

    Journal of Hepatology, Vol. 66, Núm. 6, pp. 1138-1148

  3. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection

    Clinical Gastroenterology and Hepatology, Vol. 15, Núm. 6, pp. 945-949.e1

2015

  1. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

    World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174

  2. Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153

2014

  1. Tratamiento de la hepatitis C en grupos de pacientes especiales

    Gastroenterologia y Hepatologia, Vol. 37, Núm. S1, pp. 23-36

1973

  1. AFECTACION HEPATICA EN DONANTES DE SANGRE PORTADORES DE ANTIGENO DE AUSTRALIA (AAH). II. LOCALIZACION INTRAHEPATICA DEL AAH POR IMMUNOFLUORESCENCIA

    Allergologia et Immunopathologia, Vol. 1, Núm. 5, pp. 319-320

  2. AFECTACION HEPATICA EN DONANTES DE SANGRE PORTADORES DE ANTIGENO DE AUSTRALIA (AAH). II. LOCALIZACION INTRAHEPATICA DEL AAH POR INMUNOFLUORESCENCIA

    Allergologia et Immunopathologia, Vol. 1, Núm. 4, pp. 259-268